Pergolide Mesylate: Its Effects on Circulating Anterior Pituitary Hormones in Man*

Abstract
Pergolide mesylate is a synthetic ergoline with dopamine agonist properties. The endocrine profile was studied in a double blind crossover design in six normal males. Circulating PRL, TSH, GH, LH, FSH, and cortisol were measured in the basal state and after TRH (500 μg iv) administration at 4.5, 11.5, and 23.5 h after placebo or pergolide (100 /ig orally). Pergolide caused suppression of basal PRL from 2-8 ng/ml to less than 2 ng/ml commencing 60 min after administration and persisting throughout the 23.5-h study period. For the three TRH tests, a suppression of peak PRL (mean ± SEM) response to TRH of 54.6 ±5.1 vs. 1.9 ± 0.5, 45.2 ±4.1 vs. 4.5 ± 0.6, and 34.4 ± 2.0 vsvs. 6.9 ± 1.4 ng/ml, respectively, for placebo and pergolide was noted. Basal TSH levels were unaffected by pergolide, but after pergolide the peak TSH response to the first two TRH challenges was blunted (placebo vsvs. pergolide: 12.3 ± 1.2 vsvs. 6.8 ± 1.0 and 14.8 ± 2.0 vsvs. 9.6 ± 1.0, respectively); however, the third TSH response (9.8 ± 1.1 vsvs. 9.3 ± 1.2) was not blunted after pergolide. GH secretion was stimulated by pergolide with a consistent pulse observed within 60 min of pergolide administration and an enhancement in the number and amplitude of subsequent GH pulses throughout the 24-h period. Cortisol levels rose after pergolide and returned to levels seen on the control day at 16.5 h. FSH levels were unaffected but LH levels were lowered by pergolide. Side effects including nausea, vomiting, and hypotension were observed in all subjects. Pergolide is a potent dopamine agonist with the anticipated endocrine profile and clinical effects; its long duration of actions offers promise of single daily dose therapy for hyperprolactinemia. (JClin Endocrinol Metab53: 772, 1981)

This publication has 0 references indexed in Scilit: